Rituximab-associated adverse events in nephrotic syndrome: A systematic review and meta-analysis

Objective: Rituximab (RTX) has been recommended to treat nephrotic syndrome (NS), but its safety has not been quantitatively analyzed. Methods: PubMed, Embase, and the Cochrane Register of Controlled Trials databases were searched from inception to December 31, 2023, for randomized control trials (R...

Full description

Saved in:
Bibliographic Details
Main Authors: Zixian Yu, Meijin Huang, Yunlong Qin, Xiayin Li, Yueru Zhao, Yuwei Wang, Yumeng Zhang, Anjing Wang, Mei Han, Jin Zhao, Shiren Sun
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Heliyon
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S240584402417243X
Tags: Add Tag
No Tags, Be the first to tag this record!